Skip to main content

Table 1 Demographic characteristics, lung function tests, sestrin2 results of the asthma and control groups

From: Sestrin2 is involved in asthma: a case–control study

 

Control group (n = 32)

Asthma group (n = 44)

p value

Age (years)

41.66 ± 7.74

42.95 ± 8.47

0.496

Gender, male (n, %)a

15 (46.88)

21 (47.73)

0.563

BMI (kg/m2)

26.45 ± 3.06

27.26 ± 3.98

0.338

Smoking index (pack year)

3.22 ± 7.91

2.52 ± 6.06

0.665

Treatment before enrollment

 ICS (never/former or current)

19/25

 LABA (never/former or current)

28/16

 SABA (never/former or current)

7/37

 LAMA (never/former or current)

21/13

Causes of exacerbation

Allergen exposure

9

Poor adherence

18

Respiratory infection

13

Undistinguishable

4

PEF (l/min)

318.8 ± 47.91

243.75 ± 43.18

< 0.001*

311.75 ± 36.11#

FEV1% predicted (%)

 Before treatment

91.57 ± 13.68

67.90 ± 15.66

< 0.001*

 After treatment

72.35 ± 11.78#

FVC% predicted (%)

 Before treatment

95.75 ± 11.06

82.94 ± 12.54

< 0.001*

 After treatment

90.30 ± 10.84#

FEV1/FVC ratio (%)

 Before treatment

88.80 ± 5.29

77.35 ± 14.54

< 0.001*

 After treatment

82.98 ± 2.11#

Sestrin2 (ng/mL)

 Before treatment

1.32 ± 0.48

1.75 ± 0.53

< 0.001*

 After treatment

1.56 ± 0.46#

Treatment time in hospital (days)

3.64 ± 1.95

  1. Data are presented as mean ± SD
  2. BMI body mass index, PEF peak expiratory flow, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, ICS inhaled corticosteroids, LABA long-acting beta2-agonist, SABA short-acting beta2-agonist, LAMA long-acting muscarinic antagonist
  3. * Statistically significant difference
  4. # P < 0.05, vs. before treatment
  5. aData are presented as number and rate